$5 Billion Nuclear Medicine/Radiopharmaceuticals Market by Type, Therapeutic, Application - Global Forecasts to 2023 - ResearchAndMarkets.com

DUBLIN--()--The "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023" report has been added to ResearchAndMarkets.com's offering.

The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018.

Factors such as the growing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99, are driving market growth. However, the short half-life of radiopharmaceuticals, hospital budget cuts, and high equipment prices are likely to restrain market growth.

Based on type, the nuclear medicine market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. The diagnostic radiopharmaceuticals have been segmented into SPECT and PET radiopharmaceuticals. PET radiopharmaceuticals have been further segmented into F-18, Ru-82, and other PET isotopes.

In 2017, the F-18 segment accounted for the largest share of the nuclear medicine PET radiopharmaceuticals market. F-18 is the most commonly used PET radioisotope owing to its higher half-life (110 minutes) compared to other radioisotopes. F-18 is estimated to account for 98% of the total PET radioisotopes market.

The major application areas of SPECT nuclear medicine include cardiology, lymphoma, thyroid, neurology and others (prostate cancer diagnosis, bone scans, and white cell scans). The thyroid applications segment is expected to register the highest CAGR during the forecast period.

Growth in this application segment is mainly driven by the rising demand for combinational SPECT/CT therapy owing to its enhanced imaging abilities. Moreover, with growth in the number of thyroid cancer cases, the use of radiopharmaceuticals for diagnosis of thyroid disorders is expected to increase in the next five years.

North America accounted for the largest share of the nuclear medicine market. The major factors contributing to the large share of this segment include the development of novel technologies for radioisotope production, government support, and company initiatives in the region.

Asia Pacific is expected to register the highest CAGR during the forecast period. The major factors driving the growth of this regional segment include research initiatives in Japan and the rising installations of PET scanners in India and China.

The major market players in the nuclear medicine market include Cardinal Health (US), GE Healthcare (US), and Curium (France).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Nuclear Medicine/Radiopharmaceuticals Market, By Type

7 Nuclear Medicine/Radiopharmaceuticals Market, By Application

8 Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume

9 Nuclear Medicine/Radiopharmaceuticals Market, By Region

10 Competitive Landscape

11 Company Profiles

  • Advanced Accelerator Applications
  • Bayer
  • Bracco Imaging
  • Cardinal Health
  • Curium
  • Eczacibasi-Monrol Nuclear Products
  • GE Healthcare
  • Lantheus Medical Imaging
  • Nordion

For more information about this report visit https://www.researchandmarkets.com/research/zd4xkn/5_billion?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Nuclear Medicine and Radiopharmacology

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Nuclear Medicine and Radiopharmacology